Baxter International Inc  

(Public, NYSE:BAX)   Watch this stock  
Find more results for baxter
-0.27 (-0.58%)
Real-time:   1:10PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 45.87 - 46.44
52 week 32.18 - 47.22
Open 46.39
Vol / Avg. 722,081.00/4.05M
Mkt cap 25.55B
P/E 6.97
Div/yield 0.13/1.13
EPS 6.61
Shares 550.17M
Beta 0.63
Inst. own 91%
Jul 26, 2016
Q2 2016 Baxter International Inc Earnings Call - 8:30AM EDT - Add to calendar
Jul 26, 2016
Q2 2016 Baxter International Inc Earnings Release Add to calendar
Jun 7, 2016
Baxter International Inc at Goldman Sachs Global Healthcare Conference
May 23, 2016
Baxter International Inc at UBS Global Healthcare Conference - Webcast
May 10, 2016
Baxter International Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
May 9, 2016
Baxter International Inc Investor Conference - Webcast
May 4, 2016
Baxter International Inc Annual Shareholders Meeting (Estimated)
May 3, 2016
Baxter International Inc Annual Shareholders Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 142.61% 3.94%
Operating margin 12.17% 5.58%
EBITD margin - 14.79%
Return on average assets 70.92% 1.68%
Return on average equity 152.09% 4.63%
Employees 50,000 -
CDP Score - 99 B


One Baxter Pkwy, Df2-1W
DEERFIELD, IL 60015-4625
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.

Officers and directors

Jose E. Almeida Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
James K. Saccaro Corporate Vice President and Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Marcus Schabacker M.D. Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 52
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
.. Karp Corporate Vice President, Controller
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Brik V. Eyre Corporate Vice President, President - Hospital Products
Age: 52
Bio & Compensation  - Reuters
Robert Felicelli Corporate Vice President - Quality
Age: 57
Bio & Compensation  - Reuters
Timothy P. Lawrence Corporate Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Jill M. Schaaf Corporate Vice President and President - Renal
Age: 52
Bio & Compensation  - Reuters